

**SAVE THE DATE**  
Preliminary Program



Salzburg  
Cancer  
Research  
Institute

**3<sup>rd</sup> SALZBURG BREAST CANCER TALK 01. – 02.03.2019**  
MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY

## FRIDAY, 1<sup>st</sup> MARCH

**12:30 – 13:30** Come together and Lunch Buffet

**13:30–13:35** **Welcome and introduction**

13:35–14:00 Current evidence of immunotherapy in breast cancer

Richard Greil (*Salzburg*)

Peter Schmid (*London*)

**14:00–16:15** **Adaptive Immunity**

*Chair: Richard Greil (Salzburg), Karen Willard-Gallo (Brussels)*

14:00 Tertiary Lymphoid Structures (TLS)

Karen Willard-Gallo (*Brussels*)

14:25 Change of the immune infiltrate during treatment

Roberto Salgado (*Brussels*)

14:50 TAM, NK cells and MDSC

Cecilia Garlanda (*Milan*)

15:15 TIE-2-expressing monocytes

Marie-Agnes Doucey (*Lausanne*)

15:40 Panel discussion

**16:15 – 17:00** **Coffee break**

**17:00 – 18:30** **Influence on Immunogenicity**

*Chair: Richard D. Kennedy (Belfast), Shom Goel (Boston MA)*

17:00 Influence on immunogenicity by DNA damage response deficiency

Richard D. Kennedy (*Belfast*)

17:30 Influence on immunogenicity by the microbiota

Chiara Pozzi (*Milan*)

18:00 Influence on immunogenicity by targeting CDK4/6

Shom Goel (*Boston MA*)

**19:00** **Dinner**

## SATURDAY, 2<sup>nd</sup> MARCH

**08:30 – 09:30** **Heterogeneity & Immune Escape**

*Chair: Fritz Aberger (Salzburg), Gabriel Rinnerthaler (Salzburg)*

08:30 Neoantigene heterogeneity

Marco Gerlinger (*London*)

09:00 Immune escape in breast cancer

Barbara Seliger (*Halle*)

**09:30 – 10:30** **Imaging**

*Chair: Simon Gampenrieder (Salzburg), Elisabeth de Vries (Groningen, NL)*

09:30 Imaging techniques in immuno-oncology

Dominik Berzaczy (*Vienna*)

10:00 iRECIST 1.1

Elisabeth de Vries (*Groningen, NL*)

**10:30 – 11:15** **Coffee break**

**11:15 – 13:00** **New Treatment Approaches**

*Chair: Richard Greil (Salzburg), Giuseppe Curigliano (Milan)*

11:15 Immunotherapy strategies beyond PD1/PD-L1 inhibition

Giuseppe Curigliano (*Milan*)

11:35 Targeting the adenosinergic pathway

Cornelia Quadt (*Basel, Novartis*)

11:55 Combining immunotherapy with radiotherapy

Udo Gaipl (*Erlangen*)

12:15 Panel discussion

12:55 Closing remarks

Richard Greil (*Salzburg*)

**13:00 – 14:00** **Lunch Buffet & Farewell**

The Pitter Event Center  
Rainerstrasse 6 – 8  
5020 Salzburg

[www.imlauer.com](http://www.imlauer.com)



Free WLAN-Access:  
Pitter Event Center  
PW: pitter19



**Prof. Dr. Richard Greil**  
Head of the IIIrd Medical Department  
University Hospital Salzburg  
Paracelsus Medical University  
Salzburg Cancer Research Institute (SCRI)  
Cancer Cluster Salzburg (CCS)  
Salzburg, Austria

**Prof. Peter Schmid FRCP MD PhD**  
Centre Lead, Centre for Experimental Cancer Medicine  
Director, Breast Cancer, St Bartholomew, Hospital London  
London, United Kingdom

**Karen Willard-Gallo MD PhD**  
Head, Molecular Immunology Laboratory  
Institut Jules Bordet  
Université Libre de Bruxelles  
Brussels, Belgium

**Dr. Roberto Salgado**  
Breast Cancer Translational Research Laboratory  
Department of Pathology, GZA, Institut Jules Bordet, Brussels  
Antwerp, Belgium

**Cecilia Garlanda PhD**  
Associate Professor of Clinical Pathology  
Department of Biomedical Sciences, Humanitas University  
Head of Laboratory of Experimental Immunopathology  
Humanitas Research Hospital  
Milan, Italy

**Marie-Agnès Doucey PhD MER**  
Project Leader, Department of oncology UNIL CHUV  
Ludwig Institute for Cancer Research, Lausanne Branch  
Lausanne, Switzerland

**Maria Vittoria Dieci, MD**  
Assistant Professor  
Department of Surgery, Oncology and Gastroenterology  
Istituto Oncologico Veneto IRCCS  
Division of Medical Oncology 2, University of Padova  
Padova, Italy

**Prof. Richard Kennedy MD PhD**  
McClay Professor of Medical Oncology  
Queen's University of Belfast  
Global VP and Medical Director Almac Diagnostics

**Chiara Pozzi MD PhD**  
IEO - Department of Experimental Oncology  
Mucosal Immunology and microbiota Unit  
Humanitas University  
Milan, Italy

**Shom Goel B Med Sci MBBS FRACP PhD**  
Instructor in Medicine  
Dana-Farber Cancer Institute  
Boston MA, USA

**Prof. Dr. Fritz Aberger**  
Molecular Cancer and Stem Cell Research  
Lab Department of Molecular Biology  
University of Salzburg  
Cancer Cluster Salzburg (CCS)  
Salzburg, Austria

**Dr. Gabriel Rinnerthaler**  
IIIrd Medical Department, University Hospital Salzburg  
Paracelsus Medical University  
Salzburg Cancer Research Institute (SCRI)  
Cancer Cluster Salzburg (CCS)  
Salzburg, Austria

**Marco Gerlinger MD FRCP**  
Medical Oncologist and Research Group Leader  
Translational Oncogenomics Laboratory  
Centre for Evolution and Cancer  
Institute of Cancer Research  
London, United Kingdom

**Prof. Dr. Barbara Seliger**  
Director of the Institute for Medical Immunology  
Martin Luther University, Medical Faculty  
Halle, Germany

**Dr. Simon P. Gampenrieder**  
IIIrd Medical Department, University Hospital Salzburg  
Paracelsus Medical University  
Salzburg Cancer Research Institute (SCRI)  
Cancer Cluster Salzburg (CCS)  
Salzburg, Austria

**Prof. Elisabeth G.E. de Vries MD PhD**  
Department of Medical Oncology  
University Medical Center Groningen  
University of Groningen  
Groningen, The Netherlands

**Dr. Dominik Berzaczy**  
Department of Biomedical Imaging  
and Image-guided Therapy  
Medical University of Vienna  
Vienna, Austria

**Giuseppe Curigliano MD PhD**  
University of Milan  
Director, New Drugs and Early Drug Development for  
Innovative Therapies Division  
European Institute of Oncology  
Milan, Italy

**Cornelia Quadt MD**  
Sr. Clinical Program Leader  
Translational Clinical Oncology  
Novartis Institute for Biomedical Research  
Novartis Campus  
Basel, Switzerland




**Prof. Dr. Udo Gaipl**  
Head of Radiation Immunobiology  
Universitätsklinikum Erlangen  
Department of Radiation Oncology  
Erlangen, Germany

**Organization:**  
Richard Greil, Gabriel Rinnerthaler, Simon P. Gampenrieder

**Salzburg Cancer Research Institute (SCRI) with**  
Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)  
[www.limcr.at](http://www.limcr.at) and  
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)  
[www.cccit.at](http://www.cccit.at)

in cooperation with the  
**Cancer Cluster Salzburg** | [www.cancercluster-salzburg.at](http://www.cancercluster-salzburg.at) and **AGMT gemeinnützige GmbH** | [www.agmt.at](http://www.agmt.at)

endorsed by  
ECCO: European Cancer Organisation



Kindly supported by:  
Logos of pharmaceutical industry (unrestricted educational grants)

This event will be requested for  
**7 CME credits (ECMEC®)**